Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.50 |
| ▸ | FNTB | P49356 | 5/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285484 | 0.88 | FNTA (0.47) | FNTAFNTBDRD4TACR1KMT2A | |
| SCHEMBL6285454 | 0.86 | CNR2 (0.45) | FNTAFNTBTACR1KMT2AMEN1 | |
| SCHEMBL6285229 | 0.85 | DRD4 (0.43) | FNTAFNTBDRD4AMPD2CCR2 | |
| SCHEMBL6282910 | 0.81 | BCHE (0.41) | FNTAFNTBTACR1KMT2AMEN1 | |
| SCHEMBL6283110 | 0.80 | AVPR1A (0.44) | DRD4TACR1KMT2AMEN1AVPR1A | |
| SCHEMBL6285241 | 0.79 | CBX7 (0.40) | FNTAFNTBTACR1KMT2AMEN1 | |
| SCHEMBL6282969 | 0.79 | CNR2 (0.49) | FNTAFNTBDRD4TACR1KMT2A | |
| SCHEMBL6287289 | 0.73 | BCHE (0.41) | TACR1AVPR1A | |
| SCHEMBL6285489 | 0.72 | DRD4 (0.46) | FNTAFNTBDRD4KMT2AAMPD2 | |
| SCHEMBL6278686 | 0.71 | BCHE (0.43) | TACR1KMT2AMEN1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919365-B2 | Imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1384715-A1 | NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | CMA1, TPSD1, TPSB2 | FNTA 4765/4885FNTB 4212/4885DRD4 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.